ArticleNature reviews. Clinical oncology2020
Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
Abstract readPublished Erratum
In one paragraph
Article in Nature reviews. Clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- User Comprehension and EHR Integration of theAMIA ... Annual Symposium proceedings. AMIA Symposium · 2024Article
- Factors Driving Patient Decisions to Access Electronic Health Records via a Breast Cancer Online Decision Aid linked to the Patient Portal.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2024Article
- Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420).British journal of cancer · 2023Article
- Ductal Carcinoma In Situ (DCIS) and Microinvasive DCIS: Role of Surgery in Early Diagnosis of Breast Cancer.Healthcare (Basel, Switzerland) · 2023Review
- Molecular perspective on targeted therapy in breast cancer: a review of current status.Medical oncology (Northwood, London, England) · 2022Review
- Polygenic risk scores for prediction of breast cancer risk in Asian populations.Genetics in medicine : official journal of the American College of Medical Genetics · 2022Article
- The local anesthetic ropivacaine suppresses progression of breast cancer by regulating miR-27b-3p/YAP axis.Aging · 2021Article
- Article
- Introducing a low-risk breast screening pathway into the NHS Breast Screening Programme: Views from healthcare professionals who are delivering risk-stratified screening.Women's health (London, England)Article
Corrections and comments
- Erratum for
Authors and funding
34 authors.
Nora PashayanDepartment of Applied Health Research, Institute of Epidemiology and Healthcare, University College London, London, UK.ORCID http://orcid.org/0000-0003-0843-2468
Antonis C AntoniouDepartment of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Urska IvanusEpidemiology and Cancer Registry, Institute of Oncology Ljubljana, Ljubljana, Slovenia.ORCID http://orcid.org/0000-0002-7909-522X
Laura J EssermanCarol Franc Buck Breast Care Center, University of California, San Francisco, CA, USA.
Douglas F EastonDepartment of Public Health and Primary Care, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-2444-3247
David FrenchDivision of Psychology & Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-7663-7804
Gaby SroczynskiDepartment of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT-University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria.
Per HallDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Jack CuzickWolfson Institute of Preventive Medicine, Barts and The London, Centre for Cancer Prevention, Queen Mary University of London, London, UK.
D Gareth EvansDivision of Evolution and Genomic Sciences, University of Manchester, Manchester, UK.
Jacques SimardGenomics Center, CHU de Québec - Université Laval Research Center, Québec, Canada.ORCID http://orcid.org/0000-0001-6906-3390
Montserrat Garcia-ClosasDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Rita SchmutzlerCenter of Family Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany.
Odette WegwarthMax Planck Institute for Human Development, Center for Adaptive Rationality, Harding Center for Risk Literacy, Berlin, Germany.
Paul PharoahDepartment of Public Health and Primary Care, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-8494-732X
Sowmiya MoorthiePHG Foundation, Cambridge, UK.
Sandrine De MontgolfierIRIS Institute for Interdisciplinary Research on Social Issues, Paris, France.ORCID http://orcid.org/0000-0002-4216-9379
Camille BaronUnicancer, Paris, France.
Zdenko HercegEpigenetic Group, International Agency for Research on Cancer (IARC), WHO, Lyon, France.ORCID http://orcid.org/0000-0003-4109-3154
Clare TurnbullDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Corinne BalleyguierDepartment Medical Imaging, Institut Gustave Roussy, Villejuif, France.
Paolo Giorgi RossiEpidemiology Unit, Azienda USL di Reggio Emilia - IRCCS, Reggio Emilia, Italy.
Jelle WesselingDivision of Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
David RitchieFaculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.ORCID http://orcid.org/0000-0003-4816-113X
Marc TischkowitzDepartment of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
Mireille BroedersDepartment for Health Evidence, Radboud University Medical Center, Nijmegen, Netherlands.
Dan ReiselDepartment of Women's Cancer, Institute for Women's Health, University College London, London, UK.
Andres MetspaluThe Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.ORCID http://orcid.org/0000-0002-3718-796X
Thomas CallenderDepartment of Applied Health Research, Institute of Epidemiology and Healthcare, University College London, London, UK.ORCID http://orcid.org/0000-0001-8440-9433
Harry de KoningDepartment of Public Health, Erasmus MC, Rotterdam, Netherlands.ORCID http://orcid.org/0000-0003-4682-3646
Peter DevileeDepartment of Human Genetics, Department of Pathology, Leiden University Medical Centre, Leiden, Netherlands.
Suzette DelalogeBreast Cancer Department, Gustave Roussy Institute, Paris, France.ORCID http://orcid.org/0000-0003-2106-9165
Marjanka K SchmidtDivision of Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.ORCID http://orcid.org/0000-0002-2228-429X
Martin WidschwendterDepartment of Women's Cancer, Institute for Women's Health, University College London, London, UK. M.Widschwendter@ucl.ac.uk.ORCID http://orcid.org/0000-0002-7778-8380
Funding
Cancer Research UK 20861Cancer Research UK 27223World Health Organization 001
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.